245 related articles for article (PubMed ID: 25870060)
21. Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility.
Speth C; Blum G; Hagleitner M; Hörtnagl C; Pfaller K; Posch B; Ott HW; Würzner R; Lass-Flörl C; Rambach G
Med Microbiol Immunol; 2013 Oct; 202(5):379-89. PubMed ID: 23722593
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Chemother; 2011 Apr; 23(2):102-6. PubMed ID: 21571627
[TBL] [Abstract][Full Text] [Related]
24. Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillusnidulans complex and Aspergillusterreus complex isolated from clinical specimens.
Mohamadnia A; Salehi Z; Namvar Z; Tabarsi P; Pourabdollah-Toutkaboni M; Rezaie S; Marjani M; Moniri A; Abtahian Z; Mahdaviani SA; Mortezaee V; Askari E; Sharifynia S
J Mycol Med; 2020 Sep; 30(3):101004. PubMed ID: 32534826
[TBL] [Abstract][Full Text] [Related]
25. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
[TBL] [Abstract][Full Text] [Related]
26. Prior in vitro exposure to voriconazole confers resistance to amphotericin B in Aspergillus fumigatus biofilms.
Rajendran R; Mowat E; Jones B; Williams C; Ramage G
Int J Antimicrob Agents; 2015 Sep; 46(3):342-5. PubMed ID: 25979638
[TBL] [Abstract][Full Text] [Related]
27. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
Lewis RE; Albert NP; Liao G; Wang W; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2013 May; 68(5):1148-51. PubMed ID: 23349440
[TBL] [Abstract][Full Text] [Related]
28. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
[TBL] [Abstract][Full Text] [Related]
29. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea.
Heo MS; Shin JH; Choi MJ; Park YJ; Lee HS; Koo SH; Lee WG; Kim SH; Shin MG; Suh SP; Ryang DW
Ann Lab Med; 2015 Nov; 35(6):602-10. PubMed ID: 26354348
[TBL] [Abstract][Full Text] [Related]
30. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex.
Vaezi A; Fakhim H; Arastehfar A; Shokohi T; Hedayati MT; Khodavaisy S; Rezaei-Matehkolaei A; Badiee P; Hagen F; Lass-Flörl C; Dannaoui E; Meis JF; Badali H
Mycoses; 2018 Feb; 61(2):134-142. PubMed ID: 29064123
[TBL] [Abstract][Full Text] [Related]
31. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
32. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
33. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
Hadrich I; Makni F; Neji S; Cheikhrouhou F; Bellaaj H; Elloumi M; Ayadi A; Ranque S
Med Mycol; 2012 Nov; 50(8):829-34. PubMed ID: 22587728
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
[TBL] [Abstract][Full Text] [Related]
35. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
Escribano P; Peláez T; Recio S; Bouza E; Guinea J
Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886
[TBL] [Abstract][Full Text] [Related]
36. Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species.
Lamoth F; Alexander BD; Juvvadi PR; Steinbach WJ
J Antimicrob Chemother; 2015 May; 70(5):1408-11. PubMed ID: 25558076
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
38. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
Araujo R; Pina-Vaz C; Rodrigues AG
Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
Pastor FJ; Guarro J
Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
